ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,431.60
-0.04%
Dow Jones
38,589.16
-0.15%
US Dollar vs MXN
18.4648
0.00%
Brent Oil
82.275
0.00%
Bitcoin
66,165.08
-0.04%
Registration Strip Icon for alerts Regístrate para obtener alertas en tiempo real, cartera personalizada y movimientos del mercado.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. TransCode Therapeutics Inc (RNAZ)

  7. TransCode Therapeutics Inc (RNAZ) Noticias

RNAZ TransCode Therapeutics Inc

1.1598
-0.0202 (-1.71%)
14 Jun 2024 - Cerrado
Retrasado por 15 minutos
Nombre de la Acción Símbolo de la Acción Bolsa de Valores Tipo de Valor
TransCode Therapeutics Inc RNAZ NASDAQ Acción Común
  Variación del Día (ptos.) Variación del Día (%) Último Precio Hora
Upgrade Icon
-0.0202 -1.71% 1.1598 23:00:07
Precio de Apertura Precio Mínimo Precio Máximo Precio de cierre Precio Anterior
1.14 1.14 1.28 1.20 1.18
más cotizaciones de acciones »

Noticias Recientes

Fecha Hora Fuente Noticia
14/6/202407:00EDGAR2Form 8-K/A - Current report: [Amend]
13/6/202416:06EDGAR2Form 8-K - Current report
10/6/202407:45EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
10/6/202406:00GLOBENasdaq Determines That TransCode Therapeutics Has Regained..
07/6/202415:00EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
07/6/202415:00EDGAR2Form 8-K - Current report
29/5/202408:15GLOBETransCode Therapeutics Reports Positive Data from..
20/5/202415:00EDGAR2Form DEFR14A - Revised definitive proxy soliciting materials
15/5/202416:13EDGAR2Form 8-K - Current report
13/5/202416:08EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
13/5/202407:30GLOBETransCode Therapeutics Open Letter to Shareholders
10/5/202415:50EDGAR2Form PRE 14A - Other preliminary proxy statements
10/5/202415:45EDGAR2Form 8-K - Current report
15/4/202408:00GLOBETransCode Therapeutics Announces FDA Clearance To Initiate..
03/4/202408:10GLOBETransCode Therapeutics Reports 2023 Results; Provides..
28/3/202407:30GLOBETransCode Therapeutics Announces Appointment of Daniel..
11/3/202408:00GLOBETransCode Therapeutics and Akribion Genomics Report Progress..
06/3/202415:15GLOBETransCode Therapeutics To Present At 2024 RNA Leaders Europe..
20/2/202407:00GLOBETransCode Therapeutics Reports Publication of United States..
15/2/202415:00EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
13/2/202419:12EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
31/1/202415:33EDGAR2Form 8-K - Current report
31/1/202415:05GLOBENasdaq Determines TransCode Therapeutics Compliance with..
29/1/202407:30GLOBETransCode Therapeutics and Debiopharm Announce Collaboration..
22/1/202415:45EDGAR2Form 8-K - Current report
22/1/202415:45GLOBETransCode Therapeutics Announces Closing of $7.25 Million..
19/1/202420:57EDGAR2Form 424B4 - Prospectus [Rule 424(b)(4)]
18/1/202423:15EDGAR2Form EFFECT - Notice of Effectiveness
18/1/202412:27GLOBETransCode Therapeutics Announces Pricing of $7.25 Million..
18/1/202409:39EDGAR2Form S-1/A - General form for registration of securities..
17/1/202406:06EDGAR2Form S-1/A - General form for registration of securities..
16/1/202415:01EDGAR2Form 8-K - Current report
12/1/202415:05GLOBETransCode Therapeutics Reports Further Restructuring to..
11/1/202407:22EDGAR2Form S-1 - General form for registration of securities under..
11/1/202407:00GLOBETransCode Therapeutics Announces 1-for-40 Reverse Stock..
08/1/202415:01EDGAR2Form 8-K - Current report
04/1/202411:41EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
04/1/202407:05GLOBETransCode Therapeutics Publishes Open Letter Outlining..
18/12/202315:28EDGAR2Form DEF 14A - Other definitive proxy statements
12/12/202307:30GLOBETransCode Therapeutics Reports Positive Pre-Clinical Results..
08/12/202315:57EDGAR2Form PRE 14A - Other preliminary proxy statements
08/12/202315:56EDGAR2Form 8-K - Current report
07/12/202315:30EDGAR2Form SC 13G - Statement of acquisition of beneficial..
05/12/202308:00GLOBETransCode Therapeutics To Present Phase 0 Data at 2023 San..
04/12/202316:07EDGAR2Form 8-K - Current report
04/12/202315:10GLOBETransCode Therapeutics Announces Closing of $1.2 Million..
01/12/202316:23EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
30/11/202313:53GLOBETransCode Therapeutics Announces $1.2 Million Registered..
14/11/202315:40EDGAR2Form 8-K - Current report
14/11/202315:30GLOBETransCode Therapeutics Reports Third Quarter 2023 Results;..

Su Consulta Reciente

NASDAQ
RNAZ
TransCode Therapeutics
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

México
Empresa
Negocios
Popular
Obtener la aplicación
App Store
Google Play

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados